Literature DB >> 24142395

Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.

Kosuke Tsutsumi1, Takao Ohtsuka, Minoru Fujino, Hiroshi Nakashima, Shinichi Aishima, Junji Ueda, Shunichi Takahata, Masafumi Nakamura, Yoshinao Oda, Masao Tanaka.   

Abstract

BACKGROUND: It is difficult to predict the malignant potential of pancreatic neuroendocrine tumors (PNETs) precisely. This study investigated the validity of a new grading system adopted by the World Health Organization 2010 classification to determine risk factors for recurrence of PNETs.
METHODS: Data of 70 patients with PNETs who underwent curative resection were retrospectively examined by uni- and multivariate analyses. Histopathological findings were re-reviewed by experienced pathologists. NET G1 was defined as mitotic count <2 per 10 high power fields (HPF) and/or ≤2% Ki67 index, and NET G2 as 2-20 mitosis per 10 HPF and/or 3-20% Ki67 index.
RESULTS: There were 58 patients with NET G1 and 12 with NET G2. Incidence of recurrence was 11.4%. Univariate analysis demonstrated significant risk factors for recurrence including NET G2 of histological grade (P = 0.0089), male gender (P = 0.0333), tumor size ≥ 20 mm (P = 0.0117), lymph node metastasis (P = 0.0004), liver metastasis (P < 0.0001), lymphatic invasion (P = 0.046), and neural invasion (P = 0.0002). By multivariate analysis, histological grade (hazard ratio; 59.76, P = 0.0022) and neural invasion (hazard ratio; 147.49, P = 0.0016) were significantly associated with recurrence of PNETs.
CONCLUSIONS: This study confirmed the prognostic relevance of the new grading classification and that evaluation of perineural invasion and histological grade should be considered as prognostic predictors in well-differentiated PNETs (NET G1 and G2).
© 2013 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Grading classification; Neural invasion; Pancreatic neuroendocrine tumor; Predictors of recurrence; WHO 2010 classification

Mesh:

Year:  2013        PMID: 24142395     DOI: 10.1002/jhbp.47

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  15 in total

Review 1.  Surgical resection of neuroendocrine tumors of the pancreas (pNETs) by minimally invasive surgery: the laparoscopic approach.

Authors:  Tomoki Shirota; Yuichi Nagakawa; Yatsuka Sahara; Chie Takishita; Yosuke Hijikata; Yuichi Hosokawa; Tetsushi Nakajima; Hiroaki Osakabe; Kenji Katsumata; Akihiko Tsuchida
Journal:  Gland Surg       Date:  2018-02

2.  Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified?

Authors:  Cornelius A Thiels; John R Bergquist; Danuel V Laan; Kristopher P Croome; Rory L Smoot; David M Nagorney; Geoffrey B Thompson; Michael L Kendrick; Michael B Farnell; Mark J Truty
Journal:  J Gastrointest Surg       Date:  2016-02-29       Impact factor: 3.452

3.  Impact of Snail and E-cadherin expression in pancreatic neuroendocrine tumors.

Authors:  Keiichi Yonemori; Hiroshi Kurahara; Kosei Maemura; Yuko Mataki; Masahiko Sakoda; Satoshi Iino; Shinichi Ueno; Hiroyuki Shinchi; Shoji Natsugoe
Journal:  Oncol Lett       Date:  2017-06-02       Impact factor: 2.967

Review 4.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

5.  Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.

Authors:  Alexander V Fisher; Alexandra G Lopez-Aguiar; Victoria R Rendell; Courtney Pokrzywa; Flavio G Rocha; Zaheer S Kanji; George A Poultsides; Eleftherios A Makris; Mary E Dillhoff; Eliza W Beal; Ryan C Fields; Roheena Z Panni; Kamran Idrees; Paula Marincola Smith; Clifford S Cho; Megan V Beems; Shishir K Maithel; Emily R Winslow; Daniel E Abbott; Sharon M Weber
Journal:  J Gastrointest Surg       Date:  2019-01-18       Impact factor: 3.452

6.  Risk factors for lymph node metastasis in patients with pancreatic neuroendocrine neoplasms.

Authors:  Yosuke Nakao; Hiromitsu Hayashi; Yo-Ichi Yamashita; Ofuchi Takashi; Kazuki Matsumura; Norio Uemura; Fumimasa Kitamura; Rumi Itoyama; Toshihiko Yusa; Katsunobu Taki; Tatsunori Miyata; Takaaki Higashi; Shigeki Nakagawa; Hirohisa Okabe; Katsunori Imai; Hideo Baba
Journal:  World J Clin Oncol       Date:  2022-06-24

Review 7.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

8.  Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective.

Authors:  Giovanna Muscogiuri; Barbara Altieri; Manuela Albertelli; Andrea Dotto; Roberta Modica; Luigi Barrea; Giuseppe Fanciulli; Tiziana Feola; Roberto Baldelli; Rosaria Maddalena Ruggeri; Marco Gallo; Valentina Guarnotta; Pasqualino Malandrino; Erika Messina; Mary Anna Venneri; Elisa Giannetta; Diego Ferone; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2020-05-28       Impact factor: 3.633

9.  Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm.

Authors:  Eriko Katsuta; Atsushi Kudo; Takumi Akashi; Yusuke Mitsunori; Satoshi Matsumura; Arihiro Aihara; Daisuke Ban; Takanori Ochiai; Shinji Tanaka; Yoshinobu Eishi; Minoru Tanabe
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-17       Impact factor: 4.553

10.  Overestimated Oncologic Significance of Lymph Node Metastasis in G1 Nonfunctioning Neuroendocrine Tumor in the Left Side of the Pancreas.

Authors:  Young Jin Yoo; Seok Jeong Yang; Ho Kyoung Hwang; Chang Moo Kang; Hogeun Kim; Woo Jung Lee
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.